10-K/A: Scilex Holding Files Amendment to 10-K, Addressing Executive Compensation and Governance

Sentiment:

Form 10-K/A (Amendment to Annual Report) 29 April 2025 5:00 PM

Scilex Holding Company files an amendment to its 2024 Annual Report on Form 10-K to include previously omitted information regarding executive compensation and corporate governance.

Summary

Scilex Holding Company is filing Amendment No. 1 on Form 10-K/A to its Annual Report for the fiscal year ended December 31, 2024.
The amendment includes information required in Part III (Items 10, 11, 12, 13 and 14) of Form 10-K, which was previously omitted.
The company is including the Part III information because it does not intend to file a definitive proxy statement containing the required information within the 120-day period.
The amendment restates the cover page and Part III, Items 10 through 14 of the Original Form 10-K in their entirety.
The document also contains new certifications by the principal executive officer and the principal financial officer as required by Section 302 of the Sarbanes-Oxley Act of 2002.
On April 15, 2025, the Company effected a reverse stock split of its common stock at a ratio of 1-for-35.
As of March 25, 2025, the registrant had 243,312,885 shares of common stock, par value $0.0001 per share, outstanding, on a pre-reverse stock split basis (or 6,951,796 on a post-reverse stock split basis).
As of June 30, 2024, the aggregate market value of the voting stock held by non-affiliates of the registrant was approximately $233.12 million.

Sentiment

Score: 5

Explanation: The document is primarily factual and descriptive, with no strong positive or negative sentiment expressed. The filing of an amendment suggests a need for correction, but the overall tone is neutral.

Positives

The company is providing additional transparency by including previously omitted information about executive compensation and corporate governance.
The company has a clawback policy in place to recover erroneously awarded incentive-based compensation from executive officers.

Negatives

The company is filing an amendment, indicating that the original filing was incomplete.
Sorrento's bankruptcy proceedings may have had a negative impact on Scilex, as evidenced by the related party transactions and financing arrangements.

Risks

The company's reliance on related party transactions, particularly with Sorrento, could pose a risk if Sorrento's financial situation deteriorates further.
The company's debt obligations, including the Oramed Note and Tranche B Notes, could strain its financial resources.
The company's complex financing arrangements, including royalty purchase agreements and security agreements, could create operational and financial challenges.
The company is subject to various affirmative and negative covenants that could restrict its ability to operate its business.

Industry Context

The document provides insight into the financial and operational decisions of a pharmaceutical company, which is relevant to understanding the competitive landscape and strategic positioning within the industry.

Comparison to Industry Standards

The document does not provide enough information to make a detailed comparison to industry standards.
A thorough analysis would require benchmarking Scilex's financial performance, executive compensation, and corporate governance practices against those of comparable companies in the pharmaceutical industry.
Comparable companies could include other publicly traded pharmaceutical companies with similar market capitalizations, product portfolios, and stages of development.

Legal Proceedings

Sorrento (former controlling stockholder) and its subsidiary, Scintilla Pharmaceuticals, Inc., commenced voluntary proceedings under Chapter 11 of the United States Bankruptcy Code.

Related Party Transactions

The company engaged in numerous related party transactions with Sorrento, including a stock purchase agreement, DIP financing, and legal fee assumption.
The company entered into a securities purchase agreement with Oramed Pharmaceuticals Inc.

Stakeholder Impact

The company's financial decisions and related party transactions could impact shareholders, employees, customers, suppliers, and creditors.
The reverse stock split could affect the value of shareholders' investments.
The company's debt obligations could limit its ability to invest in research and development or other growth initiatives.

Key Dates

Date	Description
January 6, 2021	Date of Warrant Agreement between Vickers Vantage Corp. I and Continental Stock Transfer & Trust Company
April 23, 2021	Date of Asset Purchase Agreement between Sorrento Therapeutics, Inc. and Aardvark Therapeutics, Inc.
May 11, 2011	Date of Product Development Agreement by and between Scilex Pharmaceuticals, Inc., Oishi Koseido Co., Ltd. and Itochu Chemical Frontier Corporation.
February 16, 2017	Date of Commercial Supply Agreement by and among Scilex Pharmaceuticals Inc., Oishi Koseido Co., Ltd. and Itochu Chemical Frontier Corporation
March 17, 2022	Date of Agreement and Plan of Merger by and among Vickers Vantage Corp. I, Vickers Merger Sub, Inc. and Scilex Holding Company
September 12, 2022	Date of Amendment No. 1 to Agreement and Plan of Merger by and among Vickers Vantage Corp. I, Vickers Merger Sub, Inc. and Scilex Holding Company
November 10, 2022	Closing date of the business combination between Vickers Vantage Corp. I and Scilex Holding Company
September 21, 2023	Date of Stock Purchase Agreement between Scilex Holding Company and Sorrento Therapeutics, Inc.
October 7, 2024	Date of Tranche B Securities Purchase Agreement between Scilex Holding Company and the Tranche B Noteholders
October 8, 2024	Date of Amendment No. 1 to Securities Purchase Agreement between Scilex Holding Company and Oramed Pharmaceuticals, Inc.
October 8, 2024	Date of Amended and Restated Security Agreement, by and among Scilex Holding Company, the Subsidiaries of the Company party thereto, Oramed Pharmaceuticals Inc. and Acquiom Agency Services LLC
February 22, 2025	Date of License Agreement (ZTlido), by and between Scilex Pharmaceuticals Inc. and Royaltyvest Ltd.
February 22, 2025	Date of Parent Guarantee for Lidocaine License Agreement, by and between Scilex Holding Company and Royaltyvest Ltd.
February 28, 2025	Date of Amendment No. 1 to Purchase and Sale Agreement, by and among Scilex Holding Company, Scilex Pharmaceuticals Inc., Oramed Pharmaceuticals Inc. and the other signatories thereto
April 1, 2025	Date used for age calculation of executive officers and directors.
March 31, 2025	Date used for calculation of beneficial ownership of common stock.
April 15, 2025	Date the Company effected a reverse stock split of its common stock at a ratio of 1-for-35.
April 29, 2025	Date of certifications of Principal Executive Officer and Principal Financial Officer.

Keywords

executive compensation, corporate governance, related party transactions, financial reporting, stock split, directors, officers, Scilex Holding Company, Form 10-K/A, amendment

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.